Glioblastoma remains one of oncology's most demoralizing challenges — median survival rarely exceeds 15 months despite decades of research. A conceptual reframe now emerging from neuro-oncology may explain why: the tumor is not merely embedded in brain tissue but is actively co-opted by the brain's own signaling architecture, turning neural circuitry into a co-conspirator of immune evasion.
This review synthesizes evidence that glioblastoma (IDH-wildtype, CNS WHO grade 4) exploits neuronal signaling molecules — most notably glutamate and neuroligin-3 (NLGN3) — to reshape its tumor microenvironment (TME) toward immunosuppression while simultaneously accelerating tumor cell proliferation. Neuronal activity, rather than being a bystander, drives downstream cascades that impair lymphocytic infiltration across the blood-brain barrier, promote T-cell exhaustion, and suppress antitumor immune responses. This dual function — growth promotion plus immune suppression mediated through the same neural signals — helps explain why CAR-T cell therapies and immune checkpoint inhibitors produce transient, non-durable responses in glioblastoma even when they work elsewhere.
What makes this neuro-immunological model intellectually significant is that it shifts the explanatory burden away from tumor-intrinsic antigen heterogeneity alone and toward a dynamic, regionally heterogeneous network in which the brain's own physiology creates immunologically hostile niches. Glutamate, for instance, is not a novel player — its role in excitotoxicity and synaptic plasticity is well established — but its function as a pro-tumorigenic immunomodulator within glioblastoma represents an underexplored therapeutic target axis. NLGN3 shedding into the TME has been shown in prior experimental work to activate PI3K-mTOR proliferative signaling, lending mechanistic specificity to these claims.
This is a review article rather than primary trial data, so its contribution is primarily conceptual synthesis rather than new empirical findings. The framework is compelling and increasingly supported by converging lines of preclinical evidence, but translating neuro-immune network disruption into durable clinical benefit remains an unsolved engineering problem. For now, this model represents an important analytical lens rather than actionable treatment guidance.